Independent Analysis Examines ColonBroom GLP-1 Booster Ingredient Transparency, Non-Prescription Supplement Category Context, and Company-Reported Formulation Details as Consumer Research Into ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Over The Counter ...
ATRIMED today shared an update on a long running research effort led in part by physician scientist Dr. Latha Damle, whose ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.
Tomer Izraeli, CEO of Polyrizon, commented, "Selecting NASARIX™ as the brand name for PL-14 allergy blocker reflects our commitment to commercial readiness and our focus on building a strong and ...
In return for $10 million upfront, Foresee sold the global rights for its MMP-12 inhibitor programs to Primevera Therapeutics ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
WASHINGTON — Federal health officials are unilaterally reducing the number of recommended pediatric immunizations in response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback